PharmiWeb.com - Global Pharma News & Resources
17-Apr-2019

Cancer Immunotherapy Drug Discovery Outsourcing Market is Project Worth USD 1.8 Billion in 2026

The Global Cancer Immunotherapy Drug Discovery Outsourcing Market size is anticipated to around USD 1.8 billion by 2026, this market is anticipated to grow with 14.0% CAGR during the forecast time period. The surge in the number of cancer patients across the globe is expected to drive the growth of the global cancer immunotherapy drug discovery outsourcing market.

The global cancer immunotherapy drug discovery outsourcing market is segmented into four major segments: drug type, service type, cancer type, and region. On the basis of drug type the cancer immunotherapy drug discovery outsourcing market is segmented into monoclonal antibodies, immunomodulators, oncolytic viral therapies and cancer vaccines, and others. On the basis of the service type the global cancer immunotherapy drug discovery outsourcing market is segmented into target identification and validation, lead screening and characterization and cell based assays. On the basis of cancer type, the cancer immunotherapy drug discovery outsourcing market is segmented into lung, breast, colorectal, melanoma, prostate, head and neck, ovarian and pancreatic. On the basis of region the global cancer immunotherapy drug discovery outsourcing market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East amp; Africa.

DOWNLOAD SAMPLE PAGES at https://www.acumenresearchandconsulting.com/request-sample/909

Lung cancer captured the largest market chunk for in 2018. Late analysis of this illness makes chemotherapy unproductive for the treatment of patients. This disadvantage can be overcome by immunotherapy as it has attested to have significant effects on NSCLC (non-small cell lung cancer) conditions. Also, obtain ability of the majority of immune therapies for NSCLC has been complementing the development of this segment.

Ovarian cancer sub-segment is expected to witness the highest CAGR during the forthcoming years due to growing research and development investments and increasing occurrence. Immunotherapies have presented optimistic results in the treatment of ovarian cancer, as it improves patientsrsquo; immune systems, which in turn bars the growth of malignant cells. The treatment of ovarian oncology treatment with immunotherapy comprise of checkpoint inhibitors and other adoptive therapies. Continuing R amp; D in this field has numerous upcoming potential drugs for the treatment that is projected to drive the growth of the ovarian cancer sub-segment over the forecast timeframe.

The monoclonal antibodies sub-segment was the crucial type of medicine in 2018. Substantiated of monoclonal antibodies and launching of improved drug types, for instance conjugated monoclonal antibodies, naked antigen-binding, and bispecific, are gauging attention of pharmaceutical companies.

Oncolytic viral therapies and cancer vaccines are quality innovations in the field of cancer immunotherapy due to continuous research and development efforts of market players. This immunotherapeutic vaccine comprises of immune cells of the patient transformed to dendritic cells by chemical treatment, which is deployed against prostate cancer. Some treatment vaccines in the pipeline compromise parts of antigens, cells, and cancer cells.

Therapeutic vaccines have been witnessed to generate anti-cancer antigen acting memory cells in the immune system of the patient. Increasing responsiveness about assistances linked with these vaccines has been enhancing investments of market participant in research and development activities. Thus, oncolytic viral therapies and cancer vaccines are expected to boost the growth of the market during the forecasted timeframe.

Increasing emphasis on novel therapeutic options is consequential in the progression of therapeutic options, for instance immune tumor infiltrating lymphocytes, checkpoint inhibitors, CAR T cell therapies. These therapies are presenting favourable results in clinical studies of lymphomasandle U.K.emia. However, side effects related with these aforementioned therapies, for instance extremely life-threatening low blood pressure issues and high fever, can hinder the growth of the market.

The key players operating in the global cancer immunotherapy drug discovery outsourcing are Crown Bioscience, Inc., Aquila BioMedical, Molecular Imaging, Inc., STC Biologics, Genscript Biotech Corporation, Explicyte, Promega Corporation, Horizon Discovery Group PLC, HD Biosciences Co., Personalis, Inc., DiscoverX Corporation, Celentyx Ltd., BPS Bioscience, Inc., and ImmunXperts SA.

These pharmaceutical amp; biotech businesses are gradually collaborating with Ramp;D institutions amp; non-profit companies to produce new drugs with better-quality efficacy. Growing acceptance of progressive treatment options for enhanced healthcare paired with increasing demand for optimum capital utilization has been affecting the opponent rivalry in the global cancer immunotherapy drug discovery outsourcing market.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

CHAPTER 4. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET BY DRUG TYPE

CHAPTER 5. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET BY CANCER TYPE

CHAPTER 6. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET BY SERVICE TYPE

CHAPTER 7. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET BY COUNTRY

CHAPTER 8. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET BY COUNTRY

CHAPTER 9. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET BY COUNTRY

CHAPTER 10. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET BY COUNTRY

CHAPTER 11. MIDDLE EAST CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET BY COUNTRY

CHAPTER 12. AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET BY COUNTRY

CHAPTER 13. COMPANY PROFILE

CHAPTER 14. RESEARCH APPROACH

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report at https://www.acumenresearchandconsulting.com/buy-now/0/909

Editor Details

Last Updated: 17-Apr-2019